Vaxcyte, Inc.
PCVX
$33.02
-$0.93-2.74%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -16.67% | -15.33% | -69.49% | -87.78% | -78.32% |
| Total Depreciation and Amortization | 61.43% | 55.79% | 47.10% | 27.67% | 19.10% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 270.16% | 260.03% | 125.42% | 13.38% | -43.62% |
| Change in Net Operating Assets | -4,376.50% | -167.50% | -135.90% | -157.77% | -95.27% |
| Cash from Operations | -12.63% | -52.51% | -101.56% | -117.96% | -114.20% |
| Capital Expenditure | -80.03% | -75.55% | -1,122.93% | -2,015.04% | -770.80% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -84.84% | -167.43% | -68.02% | 47.56% | -69.29% |
| Cash from Investing | -84.38% | -159.36% | -83.87% | 33.18% | -83.44% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 15.77% | 282.61% | 89.62% | -23.57% | 79.28% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -152.15% | -268.73% | -281.75% | -277.69% | -306.49% |
| Cash from Financing | 15.15% | 282.69% | 89.09% | -23.99% | 78.82% |
| Foreign Exchange rate Adjustments | -589.95% | 106.37% | -580.25% | -349.24% | -267.18% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -214.33% | 97.86% | 89.26% | -104.14% | 29.42% |